B. Riley Wealth Advisors Inc. cut its holdings in Inogen, Inc. (NASDAQ:INGN – Free Report) by 44.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,400 shares of the medical technology company’s stock after selling 24,800 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 0.13% of Inogen worth $302,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Franklin Resources Inc. purchased a new stake in shares of Inogen during the third quarter valued at about $139,000. Virtu Financial LLC purchased a new stake in shares of Inogen during the third quarter valued at about $111,000. Barclays PLC lifted its position in shares of Inogen by 72.9% during the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after buying an additional 23,398 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after buying an additional 5,921 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Inogen by 2.8% during the third quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock valued at $4,957,000 after buying an additional 14,054 shares during the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Friday, November 8th. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday.
Inogen Stock Up 2.0 %
Shares of Inogen stock opened at $8.48 on Friday. The firm has a market capitalization of $201.98 million, a P/E ratio of -3.77 and a beta of 1.02. The company has a 50 day moving average price of $9.46 and a 200 day moving average price of $9.72. Inogen, Inc. has a 52 week low of $5.08 and a 52 week high of $13.33.
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
- Five stocks we like better than Inogen
- What is the Dogs of the Dow Strategy? Overview and Examples
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- How to Buy Cheap Stocks Step by Step
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.